Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
Kyung Hoon Kim,1 Hye Seon Kang,2 Ju Sang Kim,3 Hyoung Kyu Yoon,4 Sung Kyoung Kim,5 Chin Kook Rhee1 1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 2Division...
Main Authors: | Kim KH, Kang HS, Kim JS, Yoon HK, Kim SK, Rhee CK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-12-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/risk-factors-for-the-discontinuation-of-roflumilast-in-patients-with-c-peer-reviewed-article-COPD |
Similar Items
-
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
by: Chin Kook Rhee, et al.
Published: (2020-03-01) -
Roflumilast: a review of its use in the treatment of COPD
by: Wedzicha JA, et al.
Published: (2016-01-01) -
Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
by: Zhang X, et al.
Published: (2018-08-01) -
Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment
by: Ita Octafia, et al.
Published: (2021-01-01) -
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
by: Hyonsoo Joo, M.D., et al.
Published: (2018-10-01)